McNeil Voluntarily Recalls Infants' Tylenol Oral Suspension Product - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

McNeil Voluntarily Recalls Infants' Tylenol Oral Suspension Product


ePT--the Electronic Newsletter of Pharmaceutical Technology

On Feb. 17, 2012, McNeil Consumer Healthcare, a division of McNeil-PPC, a subsidiary of Johnson & Johnson, voluntarily recalled approximately 574,000 bottles of its over-the-counter pain reliever and fever-reducer Infants’ Tylenol Oral Suspension, 1 oz. Grape. The voluntary recall was initiated after consumers complained of having difficulty using the SimpleMeasure dosing system.

The SimpleMeasure dosing system used for Infants’ Tylenol includes a dosing syringe that is inserted into a flow restrictor at the top of the bottle to measure dosage. Complaints were received from some consumers that the flow restrictor was pushed into the bottle when the syringe was inserted.

McNeil states, in a press release, that the voluntary recall was at the wholesale and retail level for seven lots distributed nationwide in the United States and that no adverse events have been reported. McNeil states that consumers may continue to use the product “provided that the flow restrictor at the top of the bottle remains in place,” but cautions consumers to not use the product if the flow restrictor is pushed into the bottle.

The specific lot numbers recalled were BIL0U00, BIL0V00, BIL3500, BJL2D00, BJL2E00, BJL2T00, BJL2U00, UPC Code 300450122308. Consumers can request a refund from McNeil by visiting www.tylenol.com.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here